Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which pembrolizumab (Keytruda) is a treatment option when it approved the immunotherapeutic for treating certain patients with cervical cancer and certain patients with non-Hodgkin lymphoma.
Read More
Earlier this week, the U.S. Food and Drug Administration (FDA) approved expanding the use of the immunotherapeutic tisagenlecleucel (Kymriah) to include certain patients with non-Hodgkin lymphoma.
In August 2017, tisagenlecleucel became …
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the antibody–drug conjugate brentuximab vedotin (Adcetris) to include certain patients with two types of non-Hodgkin lymphoma.
Read More
Last week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic acalabrutinib (Calquence) for treating adults who have an aggressive form of non-Hodgkin lymphoma called mantle cell …
Read More
Last week, the U.S. Food and Drug Administration (FDA) approved the second of a revolutionary new type of immunotherapy known as chimeric antigen receptor (CAR) T–cell therapy.
Read More
At the end of last week, the U.S. Food and Drug Administration (FDA) approved the immunotherapeutic obinutuzumab (Gazyva) for treating certain patients with follicular lymphoma, which is the second-most common form of non-Hodgkin lymphoma diagnosed in the United States.
Read More
Among the many types of cancer acknowledged during the month of September is lymphoma, a cancer arising from a subset of white blood cells (lymphocytes) that compose an important part …
Read More